Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Carfilzomib in multiple myeloma
ASPIRE study: Carfilzomib potent addition to multiple myeloma therapy on Vimeo
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | Journal of Clinical Oncology
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR - ScienceDirect
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Advances in the Treatment of Multiple Myeloma: Next-Generation Proteasome Inhibition
ASPIRE Trial - KRd VS Rd - Multiple Myeloma Clinical Trials
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation. - ppt download
Hematologic Malignancies - ppt download
How to Treat High-Risk Myeloma at Diagnosis and Relapse | American Society of Clinical Oncology Educational Book
PFS in KRd patients: ≥CR responders versus | Download Scientific Diagram
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
![PDF] Optimising Treatment in Relapsed, Refractory Multiple Myeloma | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/988cbd3a8c1d31834b89d3e87585b1471406be6d/4-Table1-1.png "PDF] Optimising Treatment in Relapsed, Refractory Multiple Myeloma | Semantic Scholar")
PDF] Optimising Treatment in Relapsed, Refractory Multiple Myeloma | Semantic Scholar
Updates from ASPIRE and ENDEAVOR: Multicenter phase III studies of carfilzomib for relapsed/refractory multiple myeloma on Vimeo
KRd vs Rd Study Results & Efficacy | KYPROLIS® (carfilzomib)
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial | PLOS Medicine
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Interim Results of ASPIRE Trial | Int'l Myeloma Fndn
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Progression-free and overall survival for high-risk patients with relapsed or refractory multiple myeloma (RRMM) who received carfilzomib-based regimens
